Indication
Axitinib Accord is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
Loading your page…
Loading your page…
Carcinoma, Renal Cell
Marketing Authorisation Holder: Accord Healthcare S.L.U.
EMA Authorisation: 19/09/2024
INN: axitinib
AI Drug & Interaction Analysis
Free account required
Ask Osler about Axitinib Accord: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.